308 related articles for article (PubMed ID: 28942098)
1. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
[TBL] [Abstract][Full Text] [Related]
2. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
3. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States.
Mougalian SS; Soulos PR; Killelea BK; Lannin DR; Abu-Khalaf MM; DiGiovanna MP; Sanft TB; Pusztai L; Gross CP; Chagpar AB
Cancer; 2015 Aug; 121(15):2544-52. PubMed ID: 25902916
[TBL] [Abstract][Full Text] [Related]
4. Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma.
Castaneda CA; Flores R; Rojas K; Flores C; Castillo M; Milla E
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):149-56. PubMed ID: 25300565
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy.
O'Neil DS; Nietz S; Buccimazza I; Singh U; Čačala S; Stopforth LW; Joffe M; Jacobson JS; Neugut AI; Crew KD; Ruff P; Cubasch H
Oncologist; 2019 Jul; 24(7):933-944. PubMed ID: 30518615
[TBL] [Abstract][Full Text] [Related]
6. Patients' experiences with decisions on timing of chemotherapy for breast cancer.
de Ligt KM; Spronk PER; van Bommel ACM; Vrancken Peeters MTFD; Siesling S; Smorenburg CH;
Breast; 2018 Feb; 37():99-106. PubMed ID: 29128583
[TBL] [Abstract][Full Text] [Related]
7. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
9. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
[TBL] [Abstract][Full Text] [Related]
15. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit.
Spronk PER; Volders JH; van den Tol P; Smorenburg CH; Vrancken Peeters MTFD
Eur J Surg Oncol; 2019 Feb; 45(2):110-117. PubMed ID: 30348601
[TBL] [Abstract][Full Text] [Related]
16. Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts' experiences in the Netherlands.
Spronk PER; de Ligt KM; van Bommel ACM; Siesling S; Smorenburg CH; Vrancken Peeters MTFD;
Patient Educ Couns; 2018 Dec; 101(12):2111-2115. PubMed ID: 30054106
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients.
Sasanpour P; Sandoughdaran S; Mosavi-Jarrahi A; Malekzadeh M
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2423-2427. PubMed ID: 30255695
[TBL] [Abstract][Full Text] [Related]
18. Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer.
Murphy BL; L Hoskin T; Heins CDN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 Sep; 24(9):2518-2525. PubMed ID: 28484921
[TBL] [Abstract][Full Text] [Related]
19. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
[TBL] [Abstract][Full Text] [Related]
20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
